Working... Menu

Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03618602
Recruitment Status : Recruiting
First Posted : August 7, 2018
Last Update Posted : August 7, 2018
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Information provided by (Responsible Party):
Shanghai Theorion Pharmaceutical Co Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 2020
  Estimated Study Completion Date : July 2020